BridgeBio Pharma (BBIO) Insider Trading & Ownership $55.94 +1.02 (+1.85%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BridgeBio Pharma (NASDAQ:BBIO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage18.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)11Amount OfInsider Selling(Last 12 Months)$732.58M Get BBIO Insider Trade Alerts Want to know when executives and insiders are buying or selling BridgeBio Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBIO Insider Buying and Selling by Quarter BridgeBio Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/8/2025Neil KumarCEOSell40,000$54.78$2,191,200.00 9/22/2025Gilbert Ray Cisneros, Jr.U.S. Congress Member (D-CA)Buy$51.54$1,001 - $15,0009/5/2025Frank MccormickDirectorSell74,000$53.16$3,933,840.00 9/4/2025Neil KumarCEOSell40,000$51.34$2,053,600.00 8/21/2025Thomas TrimarchiCFOSell42,237$49.48$2,089,886.76 8/20/2025Neil KumarCEOSell26,156$48.82$1,276,935.92 8/18/2025Thomas TrimarchiCFOSell17,353$50.23$871,641.19 8/11/2025Charles J HomcyDirectorSell50,000$48.00$2,400,000.00 8/8/2025Charles J HomcyDirectorSell250,000$46.05$11,512,500.00 8/8/2025Gilbert Ray Cisneros, Jr.U.S. Congress Member (D-CA)Buy$46.58$1,001 - $15,0008/7/2025Maricel ApuliCAOSell1,000$45.44$45,440.00 8/7/2025Neil KumarCEOSell40,000$45.45$1,818,000.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/5/2025Andrea EllisDirectorSell17,167$49.00$841,183.00 7/1/2025Neil KumarCEOSell40,000$42.54$1,701,600.00 6/27/2025Global Investors Lp VikingMajor ShareholderSell3,500,000$44.00$154,000,000.00 6/26/2025Hannah ValantineDirectorSell2,418$44.05$106,512.90 6/26/2025Hannah ValantineDirectorSell2,289$44.05$100,830.45 6/24/2025Frank MccormickDirectorSell100,000$44.23$4,423,000.00 6/10/2025Hannah ValantineDirectorSell4,292$40.00$171,680.00 5/20/2025Neil KumarCEOSell75,000$33.40$2,505,000.00 5/19/2025Neil KumarCEOSell26,156$33.33$871,779.48 5/12/2025Genetic Disorder L.P. KkrMajor ShareholderSell6,000,000$34.20$205,200,000.00 5/2/2025Andrew LoDirectorSell100,000$38.50$3,850,000.00 5/2/2025Maricel ApuliCAOSell1,026$38.51$39,511.26 4/22/2025Neil KumarCEOSell75,000$34.11$2,558,250.00 4/14/2025Andrea EllisDirectorSell10,000$35.00$350,000.00 4/1/2025Andrea EllisDirectorSell30,000$34.05$1,021,500.00 3/25/2025Neil KumarCEOSell75,000$36.87$2,765,250.00 3/5/2025Genetic Disorder L.P. KkrMajor ShareholderSell6,000,000$32.96$197,760,000.00 2/25/2025Brian C StephensonCFOSell8,500$33.19$282,115.00 2/25/2025Neil KumarCEOSell75,000$33.57$2,517,750.00 2/19/2025Brian C StephensonCFOSell4,148$36.16$149,991.68 2/19/2025Neil KumarCEOSell31,543$36.14$1,139,964.02 1/31/2025Global Investors Lp VikingMajor ShareholderSell3,065,616$34.90$106,989,998.40 1/28/2025Brian C StephensonCFOSell68,000$36.29$2,467,720.00 1/28/2025Neil KumarCEOSell326,932$36.29$11,864,362.28 11/19/2024Brian C StephensonCFOSell4,156$22.41$93,135.96 11/19/2024Neil KumarCEOSell27,389$22.41$613,787.49 (Data available from 1/1/2013 forward) BBIO Insider Trading Activity - Frequently Asked Questions Who is on BridgeBio Pharma's Insider Roster? The list of insiders at BridgeBio Pharma includes Andrea Ellis, Andrew Lo, Brian C Stephenson, Charles J Homcy, Frank Mccormick, Genetic Disorder L.P. Kkr, Global Investors Lp Viking, Hannah Valantine, Maricel Apuli, Neil Kumar, Randal W Scott, and Thomas Trimarchi. Learn more on insiders at BBIO. What percentage of BridgeBio Pharma stock is owned by insiders? 18.20% of BridgeBio Pharma stock is owned by insiders. Learn more on BBIO's insider holdings. Which BridgeBio Pharma insiders have been selling company stock? The following insiders have sold BBIO shares in the last 24 months: Andrea Ellis ($2,212,683.00), Andrew Lo ($3,850,000.00), Brian C Stephenson ($3,095,549.59), Charles J Homcy ($13,912,500.00), Frank Mccormick ($12,562,840.00), Genetic Disorder L.P. Kkr ($552,310,000.00), Global Investors Lp Viking ($260,989,998.40), Hannah Valantine ($489,705.90), Maricel Apuli ($84,951.26), Neil Kumar ($34,553,713.60), Randal W Scott ($193,840.00), and Thomas Trimarchi ($2,961,527.95). How much insider selling is happening at BridgeBio Pharma? Insiders have sold a total of 26,190,337 BridgeBio Pharma shares in the last 24 months for a total of $887,217,309.70 sold. Which members of congress are trading BridgeBio Pharma? Gilbert Ray Cisneros, Jr. (D-CA) has bought shares of BridgeBio Pharma in the last year totaling $16,000. BridgeBio Pharma Key ExecutivesDr. Neil Kumar Ph.D. (Age 45)Co-Founder, President, CEO & Director Compensation: $1.53MDr. Charles J. Homcy M.D. (Age 76)Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director Compensation: $563.2kDr. Frank P. McCormick Ph.D. (Age 74)Co-Founder, Chairman of Oncology & Director Compensation: $542.78kDr. Brian C. Stephenson C.F.A. (Age 43)Ph.D., CFO & Secretary Compensation: $1.15MDr. Richard H. Scheller Ph.D. (Age 71)Chairman of Research & Development Compensation: $509.62kDr. Uma Sinha Ph.D. (Age 66)Chief Scientific Officer Compensation: $1.31MGrace RauhVice President of CommunicationsMr. Eli M. Wallace Ph.D. (Age 57)Chief Scientific Officer of Oncology Dr. Thomas Trimarchi Ph.D.Chief Product OfficerDr. Eric Michael David J.D. (Age 52)M.D., Ph.D., Chief Executive Officer of Gene Therapy More Insider Trading Tools from MarketBeat Related Companies BeOne Medicines Insider Selling Insmed Insider Selling BioNTech Insider Selling Teva Pharmaceutical Industries Insider Selling Genmab A/S Insider Selling Summit Therapeutics Insider Selling Viatris Insider Selling Roivant Sciences Insider Selling Moderna Insider Selling Elanco Animal Health Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Healthcare Companies Insiders Are Buying Marvell Insiders Buy Shares—Should Investors Follow Suit?This Insider Just Made a Massive Bet on Transocean's ComebackInsider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t Worry This page (NASDAQ:BBIO) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
